Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (2010)	1/6/2004 12:55:54 PM
From: bob zagorin	Respond to of 3044

i sold too as the stock was up significantly. of course it has rebounded some since i sold this morning:)

To: Ian@SI who wrote (2010)	1/6/2004 5:30:18 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3044

What about NSCLC, PC, Ovarian, H&N,...??? Those were Irino refractory pts, and point was to observe could Velcade re-sensitize this population for Irino, as third line therapy. Similar to what IMCL did done with C225 (and they did try to cheat with Irino-stable!!!). Fact they Velcade didn’t have efficacy here does not say anything about overall (or specific) activity in solid tumor. BTW, Irino refractory and metastatic (after Irino second line failure) is one of the hardest CRC-indication. Miljenko